Alzamend Neuro (NASDAQ:ALZN – Get Free Report) had its price objective cut by equities researchers at Ascendiant Capital Markets from $32.00 to $20.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock.
Alzamend Neuro Stock Down 1.8 %
Shares of ALZN stock opened at $0.68 on Monday. Alzamend Neuro has a 52 week low of $0.64 and a 52 week high of $15.06. The company has a 50-day simple moving average of $1.02 and a 200 day simple moving average of $1.36.
Alzamend Neuro (NASDAQ:ALZN – Get Free Report) last posted its earnings results on Monday, March 10th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.10. Equities research analysts predict that Alzamend Neuro will post -1.68 earnings per share for the current year.
Institutional Investors Weigh In On Alzamend Neuro
Alzamend Neuro Company Profile
Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
See Also
- Five stocks we like better than Alzamend Neuro
- What Are Dividend Champions? How to Invest in the Champions
- Meta Platforms: Can LLaMA Drive Long-Term Stock Growth?
- Manufacturing Stocks Investing
- 3 Unique and Dominant Consumer Staples ETF Plays
- What Does Downgrade Mean in Investing?
- 3 Dividend Stocks Offering Higher Yields and Bullish Forecasts
Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.